In the Phase 2a INFORM-MS trial, Tiziana’s nasal foralumab reduced microglial activation on PET imaging at 50 µg in non-active secondary progressive MS, while the 100-µg dose showed no significant effect.
|Articles|May 15, 2002
- BioPharm International-05-01-2002
- Volume 15
- Issue 5
Outsourcing Outlook: E-Procurement ? Successfully Using and Managing Reverse Auctions
Author(s)Jim Miller, Edward P. Miller
by Jim Miller, and Edward P. Miller, PharmSource Informaton Services, Inc. Today, reverse auctions are perceived more realistically than in years past, but they still offer many benefits for both buyer and seller.
Advertisement
Articles in this issue
over 24 years ago
Info+over 24 years ago
Analytical Advances: Strategies in Clarifying Mammalian Culturesover 24 years ago
Analytical Advances: Using Image Informatics - Focusing Proteomicsover 24 years ago
The Not-So-Sure Thingover 24 years ago
Washington Report: Vaccine Shortages put Spotlight on Productionover 24 years ago
Guest Editorial: Validation Bingoover 24 years ago
Travel Notes: Yes, Virginia, There is Biotech in the CommonwealthAdvertisement
Related to this article
The deal adds five US sites and about 1,100 employees, more than doubling Lonza’s US network and filling a gap in US bioconjugation capacity the company flagged weeks earlier.
CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
AAPS PharmSci 360 2026 in New Orleans centered on auditable AI, modeling-guided formulation, oral peptide delivery, high-concentration antibody suspensions, and the push toward $10-per-gram monoclonal antibodies.
Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
The deal gives Fresenius options on biosimilars spanning monoclonal and bispecific antibodies, ADCs, and fusion proteins, starting with polatuzumab vedotin and teprotumumab, and could expand its portfolio from 29 to 66 molecules.
FDA set a May 1, 2027 target date for AMT-130, a one-time gene therapy that silences the huntingtin gene, and plans an advisory committee meeting.
Inovio reports that Voceryq spared 27% of adults with recurrent respiratory papillomatosis from surgery for 12 months in a 26-patient efficacy group.
Advertisement
Advertisement
Trending on BioPharm International
1
Fresenius and WuXi Biologics Sign Exclusive Agreement Covering Up to 37 Biosimilar Candidates
2
Samsung Biologics Secures 97.66% of PolyPeptide Shares in Tender Offer
3
FDA Grants Accelerated Approval to Inovio DNA Immunotherapy for RRP
4
Drug Digest: Reshoring Manufacturing and Securing Cold-Chain Supply for Biopharma
5